ArticleiScience2026
Exome sequencing and metabolite profiling identifies genetic variants associated with altered metabolism in early-onset schizophrenia.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early-onset schizophrenia (EOS) is a severe psychiatric disorder characterized by strong genetic contribution and metabolic alterations, including lipid dysregulation. To investigate the relationship between genetic variation and metabolic changes in EOS, we performed whole-exome sequencing and serum metabolome profiling in 28 patients with EOS and 20 healthy controls. We identified 114 high-risk genes and 117 differentially expressed metabolites. Of the risk genes with variants in multiple patients, 54.35% (25/46) were associated with clinical symptoms, and of the differentially expressed lipids, 34.88% (15/43) were correlated with clinical symptoms. By integrating protein-metabolite interactions and metabolite correlations, we constructed a gene-metabolite network and identified 19 high-risk genes linking to 31 dysregulated lipids. Twenty of these lipids were significantly down-regulated in patients, with 80% (16/20) showing further down-regulation in variant carriers. Our findings provide compelling evidence for a genetic-metabolic interaction in EOS pathogenesis and point to an alternative disease mechanism of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.